Mesna clinical trials
Mesna is named as an intervention in 6 current clinical trials in our Canada, USA, Israel, Australia and Mexico registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is CERo Therapeutics Holdings, Inc (1). The most-studied condition is AML.
Where Mesna is approved
All regulators →Of the three regulators tracked here, the first to approve Mesna was the US, on 30 Dec 1988. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Mesna
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Mesna works
All drug targets →- Ewing sarcomaPhase 3
- Acute lymphoblastic leukemiaPhase 3
- Acute myeloid leukemiaPhase 3
- Diffuse large B-cell lymphomaPhase 3
- NeuroblastomaPhase 3
- Non-Hodgkin lymphomaPhase 3
- Soft tissue sarcomaPhase 3
- Acute kidney injuryPhase 2/3
- Acute kidney tubular necrosisPhase 2/3
- Neuromyelitis opticaPhase 2/3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL975, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Mesna
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 3 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Mesna
- ChEMBL
- CHEMBL975
- PubChem CID
- 173117269
- CAS number
- 19767-45-4
- FDA UNII
- NR7O1405Q9
- Wikidata
- Q424997
- Wikipedia
- Mesna
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Mesna
6 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Mesna across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
3 single-substance products containing Mesna on the HPRA medicines list.
- Uromitexan 100mg/ml Solution for Injection or InfusionBaxter Holding B.V. · PA2299/024/001 · Marketed
- Uromitexan Tablets 600mgBaxter Holding B.V. · PA2299/024/003 · Marketed
- Uromitexan tablets 400 mgBaxter Holding B.V. · PA2299/024/002 · Marketed
Supply shortages
- Uromitexan MultidoseGermany (BfArM) · Production problem · 1 Jul 2026 to 31 Oct 2026
Conditions studied with Mesna
17 conditionsAll 17 conditions
| Condition (as registered) | Trials |
|---|---|
| AML | 1 |
| Acute Myeloid Leukemia | 1 |
| Refractory Acute Myeloid Leukemia | 1 |
| NHL | 1 |
| Multiple Myeloma | 1 |
| Blood Cancer | 1 |
| Refractory Non-Hodgkin Lymphoma | 1 |
| Central Nervous System Nongerminomatous Germ Cell Tumor | 1 |
| Choriocarcinoma | 1 |
| Embryonal Carcinoma | 1 |
| Immature Teratoma | 1 |
| Lymphoma | 1 |
| CNS Embryonal Tumor | 1 |
| CNS, Medulloblastoma | 1 |
| Atypical Teratoid Rhabdoid Tumor | 1 |
| Medulloblastoma, Childhood | 1 |
| B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| CERo Therapeutics Holdings, Inc | 1 |
| Indapta Therapeutics, INC | 1 |
| Children's Oncology Group | 1 |
| Canadian Cancer Trials Group | 1 |
| C17 Council | 1 |
| National Cancer Institute (NCI) | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Canada | 3 | 2 |
| Clinical trials in USA | 2 | 2 |
| Clinical trials in Israel | 2 | 1 |
| Clinical trials in Australia | 1 | 1 |
| Clinical trials in Mexico | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Mesna trials
How many clinical trials are testing Mesna?
6 current trials in our Canada, USA, Israel, Australia and Mexico registers name Mesna (also registered as D-7093) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Mesna trials recruiting patients?
Yes. 4 of the 6 trials are recruiting: 2 with sites in Canada, 2 with sites in USA, 1 with sites in Israel and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Mesna clinical trials?
CERo Therapeutics Holdings, Inc (1), Indapta Therapeutics, INC (1), Children's Oncology Group (1) and Canadian Cancer Trials Group (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Mesna licensed in Ireland?
Yes. The HPRA medicines list includes 3 single-substance products containing Mesna, for example Uromitexan 100mg/ml Solution for Injection or Infusion (Baxter Holding B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Mesna shortage?
The registers we track list 1 entry for Mesna: 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Mesna works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Mesna works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Mesna (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.